Clinical trials: Pulmonary Artery Hypertension
Pulmonary Hypertension, Pulmonary Arterial Hypertension
The Qutenza Patch as Treatment for Disabling Treprostinil (Remodulin) Infusion Site Pain
Subcutaneous treprostinil (Remodulin) is effective therapy for pulmonary arterial hypertension, a life threatening disease of the lung blood vessels.
- Trial name
- NCT01260454
- Testing
- Qutenza (8% capsaicin)
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Rochester
Exercise-induced Pulmonary Arterial Hypertension
An Open-Label Uncontrolled Study of the Safety and Efficacy of Ambrisentan in Participants With Exercise-Induced Pulmonary Arterial Hypertension (PAH)
The purpose of this study is assess whether ambrisentan can help people with exercise- induced pulmonary arterial hypertension (EIPAH).
- Trial name
- EiPAH (NCT01338636)
- Testing
- Ambrisentan
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Brigham and Women's Hospital
Scleroderma, Systemic, Hypertension, Pulmonary
Stress Echocardiography in the Detection of Pulmonary Arterial Hypertension in Systemic Sclerosis Patients
The purpose of this study is to assess the value in terms of sensitivity, specificity and likelihood ratio of the stress echocardiography in the screening of pulmonary arterial hypertension in patients with systemic sclerosis and…
- Trial name
- NCT01202045
- Where
- Canada
- Sponsor
- Paul Farand
Associated Pulmonary Arterial Hypertension
To Compare the Efficacy of Combination Therapy vs Monotherapy for Pulmonary Arterial Hypertension in Systemic Sclerosis
The study will be carried out on 50 consecutive consenting patients of systemic sclerosis with PAH recruited from outpatient department of internal medicine and rheumatology clinic of PGIMER, Chandigarh, India It is a single…
- Trial name
- BosSilSS (NCT03053739)
- Testing
- Sildenafil 20mg and Bosentan 62.5mg
- Where
- India
- Volunteers
- 50 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Pulmonary Arterial Hypertension
Assessing the Utility of Submaximal CPET in Treatment Management of PAH
Pulmonary hypertension (PH) is associated with worsening breathlessness and exercise capacity, right-heart failure, and adverse outcomes including increased mortality.
- Trial name
- NCT05977933
- Testing
- Shape II CPET
- Where
- 6 sites in United States
- Volunteers
- 550 people
- Sponsor
- Shape Medical Systems, Inc.
Hypertension, Pulmonary
Long-Term Open-Label, Safety Study Of Sitaxentan Sodium In Japanese Pulmonary Arterial Hypertension Patients
The safety and efficacy at 100 mg once daily for oral dose of sitaxentan sodium were demonstrated in the STRIDE clinical trial program. Sitaxentan sodium was approved in the EU, Canada and Australia.
- Trial name
- NCT01210443
- Testing
- Sitaxentan
- Where
- 2 sites in Japan
- Volunteers
- 2 people
- Sponsor
- Pfizer
Hypertension, Pulmonary
The Role of Echocardiographic Contrast (Optison) in Enhancing Tricuspid Regurgitation Spectral Doppler Signals
The investigators aim to correlate noninvasive pulmonary artery systolic pressure (PASP) measurements obtained with and without echocardiographic contrast (Optison) during transthoracic echocardiography (TTE) with those obtained…
- Trial name
- NCT02560116
- Where
- United States
- Sponsor
- Northwell Health
Pulmonary Arterial Hypertension
Pharmacokinetics, Safety and Efficacy of BIA 5-1058 in PAH (Zamicastat)
This Study evaluates the pharmacokinetic (PK) profile of different zamicastat doses in Pulmonary arterial hypertension (PAH) patients to find the most promising therapeutic dosage range for the treatment of PAH disease
- Trial name
- NCT04316143
- Testing
- Oral zamicastat
- Where
- 13 sites in Austria, Germany and 5 more
- Volunteers
- 33 people
- Sponsor
- Bial - Portela C S.A.
Coronary Artery Disease, Diabete Mellitus
Assessment and Management of Multiple Drug Use in Elderly Chronic Disease Patients
The purpose of this observational study is to understand the impact of polypharmacy on the prognosis of elderly patients with chronic diseases.
- Conditions
- Coronary Artery Disease, Diabete Mellitus, Chronic Kidney Disease, Hypertension
- Trial name
- NCT07180368
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Xijing Hospital
Pulmonary Arterial Hypertension
Investigational Trial to Evaluate Safety and Tolerability of Treprostinil in Children Diagnosed With PAH
The goal of this clinical trial is to evaluate safety and tolerability of preservative-free parenteral treprostinil in paediatric patients with PAH (PH Group 1) who are below 18 years of age.
- Trial name
- NCT06350032
- Testing
- preservative-free parenteral treprostinil
- Where
- 5 sites in Austria, France and 3 more
- Volunteers
- 20 people
- Sponsor
- AOP Orphan Pharmaceuticals AG
Hypertension, Pulmonary
A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option
The purpose of the study is to enable participants with pulmonary hypertension (PH) currently treated with study intervention(s) in a clinical study (parent studies [NCT03422328, NCT03904693,NCT04565990, NCT02932410, NCT03492177…
- Trial name
- PLATYPUS (NCT05179876)
- Testing
- Macitentan, Selexipag, Macitentan/Tadalafil FDC
- Where
- 45 sites in Belarus, Belgium and 11 more
- Volunteers
- 280 people
- Sponsor
- Actelion
Pulmonary Arterial Hypertension
Sildenafil to Tadalafil in Pulmonary Arterial Hypertension (SITAR)
Assess tolerability, transition methods and clinical effects of transition from sildenafil (Revatio) to tadalafil (Adcirca) for treatment of pulmonary arterial hypertension.
- Trial name
- SITAR (NCT01043627)
- Where
- 3 sites in United States
- Volunteers
- 100 people
- Sponsor
- Mayo Clinic
Pulmonary Arterial Hypertension, Connective Tissue Diseases
REgistry of Pulmonary Arterial Hypertension Associated With CONNECTIVE Tissue Diseases (RECONNECTIVE)
The RECONNECTIVE Registry is an observational single center study, focused on the subgroup of precapillary pulmonary hypertension related to connective tissue diseases.
- Trial name
- RECONNECTIVE (NCT05665556)
- Where
- Mexico
- Volunteers
- 170 people
- Sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Pulmonary Arterial Hypertension
A Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension (Core OLE)
The purpose of this study is to assess the safety and efficacy of Rodatristat Ethyl in pulmonary arterial hypertension (PAH) patients.
- Trial name
- NCT04712669
- Testing
- rodatristat ethyl 300 mg tablet BID, rodatristat ethyl 600 mg BID
- Where
- 64 sites in United States, Austria and 15 more
- Volunteers
- 108 people
- Sponsor
- Altavant Sciences GmbH
Pulmonary Arterial Hypertension
Patient Reported Outcomes in Pulmonary Arterial Hypertension
Develop a brief, new, patient reported outcome instrument that is valid for use in clinical practice and clinical trials.
- Trial name
- PROPAH (NCT01792622)
- Testing
- Interview, Questionnaire
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Angina, Pulmonary Arterial Hypertension
Ranolazine and Pulmonary Hypertension
The purpose of the study is to determine if the medication, ranolazine (study drug), can help improve blood flow to your heart, increase your exercise capacity and improve your quality of life (QOL).
- Trial name
- NCT01174173
- Testing
- Ranolazine
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Northwestern University
Pulmonary Hypertension
Effects of Spironolactone on Collagen Metabolism in Patients With Pulmonary Arterial Hypertension
The purpose of this study is to determine the effects of spironolactone on collagen markers in a large number of patients with pulmonary hypertension.
- Trial name
- NCT01468571
- Testing
- Spironolactone
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Baylor College of Medicine
Pulmonary Arterial Hypertension
Clinical Study to Assess the Long-term Safety, Tolerability, and Efficacy of Macitentan in Subjects With Eisenmenger Syndrome
Long-term study to evaluate if macitentan is safe, tolerable and efficient enough to be used for treatment of Eisenmenger syndrome.
- Trial name
- MAESTRO-OL (NCT01739400)
- Testing
- Macitentan 10 mg tablet, once daily.
- Where
- 51 sites in United States, Austria and 17 more
- Volunteers
- 217 people
- Sponsor
- Actelion
Pulmonary Arterial Hypertension, Right Ventricular Dysfunction
Consistency of Electrical Cardiometry and Pulmonary Artery Catheter
Currently, the gold standard method to estimate CO in patients with PAH or RV dysfunction is pulmonary artery catheter (PAC), however, the invasiveness and complexity of PAC has limited its usefulness in many clinical scenarios.
- Trial name
- NCT05587400
- Testing
- passive leg raising, dobutamine test, inhaled nitric oxide
- Where
- China
- Volunteers
- 199 people
- Sponsor
- Shanghai Zhongshan Hospital
Pulmonary Arterial Hypertension
Extension to CQTI571A2102 to Evaluate Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
This study was an extension to study CQTI571A2102 and was to evaluate the long-term safety, tolerability and efficacy of QTI571 (imatinib) in severe pulmonary arterial hypertension patients.
- Trial name
- NCT01392495
- Testing
- Imatinib
- Where
- 7 sites in United States, Australia and 5 more
- Volunteers
- 17 people
- Sponsor
- Novartis Pharmaceuticals